Ayoxxa, diabetic retinopathy, Lunaris Insight into biomarkersAYOXXA’s LUNARIS platform:?In a case study "Translational proteomics: a new perspective for ophthalmology research, Ayoxxa gives insights into the capabilities of its Lunaris multiplex protein … more ➔
Bright future for biomanufacturersProgress in process engineering and media optimisation has resulted in significant productivity increases in upstream processing driving transformations at drug developers and CDMOs. At BPI Europe in … more ➔
CRISPR & Co.: Brave new foodThe possibilities offered by CRISPR/Cas9, TALENs and other new genome editing technologies are making the mouths of plant breeders water – and not just because the methods give seed developers new options … more ➔
Checkpoint modulation: Blocking the tumour...Belgian, Swiss, and US researchers have found a new way to boost efficacy in cancer immunotherapy. In mid-April, they reported that cancer cells actively block tumour infiltration of cytotoxic T cells, … more ➔
Cleaning up the oceansFrench green chemistry pioneer, Carbios SA (Clermont-Ferrand) announced in March that it has secured equity financing of €2.5m from Kepler Cheuvreux through the acquisition of 380,000 shares over 24 … more ➔
Acquisition: Thermo enters CMO worldLab equipment giant Thermo Fisher Scientific Inc. is growing even bigger. more ➔
Orphan drugs: Treating a raritySince US senators in February conveyed the impression that drug developers might have misused market monopolies related to orphan drugs (ODs) to overprice their compounds, the status has come under closer … more ➔
Allergies: Public Enemy Number OneThe concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce … more ➔
Update of bioeconomy strategy unsureUncertainty regarding the amount of future funding and political support from the European Commission for the bioeconomy is set to hamper investments into the switch from oil-based industry production … more ➔
Serialisation: Time is running outDrug makers have only until two years from now to make their drugs and packaging counterfeit-resistant. By 9 February, 2019, every prescription drug pack must carry a 2D data matrix code that can be … more ➔